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ANSWER
From the question on page 210
This case describes an extremely rare condition of extramedul-
lary plasmacytoma (EMP) hidden in the middle media-stinum,
giving no systemic signs but causing severe central airway
narrowing detectable by the pattern of the flow-volume loop.
The constant expiratory and inspiratory flow limitation is
consistent with severe fixed narrowing of the central airway.1
Accurate analysis of the flow-volume curve pattern at the onset
of symptoms would have given rise to a suspicion of tracheal
compression several months earlier.
Fixed intrathoracic airway obstruction is usually due to
intramural infiltration (post-endotracheal intubation, recurrent
polychondritis, primitive tracheobronchial neoplasia and amyloi-
dosis) or to extrinsic compression (intrathoracic goitre, thymoma,
lymphoma).2 Mediastinal localisation of plasma-cytoma is very
uncommon, usually presenting as a large mass visible on the chest
radiograph.3 In this case, EMP was hidden in the middle
mediastinum and could only be detected on the chest CT scan.
Transbronchial biopsy was consistent with IgG lambda
plasmacytoma. Multiple Russell bodies on PAS staining were
indicative of cytoplasmic inclusions of immunoglobulins. The
results of immunohistochemical staining are shown in fig 1.
EMP is a plasma cell neoplasm of soft tissue without bone
marrow involvement or other systemic characteristics of
multiple myeloma, representing about 3% of all plasma cell
neoplasms.4 It can be differentiated from reactive plasmacytoma
and plasma cell granuloma or lymphoma (MALT, marginal and
immunoblastic) by the expression of specific cell surface
markers.5
This case suggests that the pattern of the flow-volume loop
may give a hint of central airways narrowing caused by hidden
masses not visible by traditional procedures.
Thorax 2009;64:264. doi:10.1136/thx.2008.100024a
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Figure 1 Immunohistochemical analysis of the proliferating cells phenotypically characterised to be (A) CD138+, CD79a+, (B) cIgG lambda+ (weak),
(C) cIgG kappa- and cytokeratin AE1/32. Staining for cIgM, cIgD, cIgA, cIgE, CD3 and CD45RO were all negative. Since there were very few non-
neoplastic (cIg-kappa+) plasma cells and small lymphocytes, these findings were suggestive of IgG lambda plasmacytoma.
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